LKC Technologies has partnered with Welch Allyn for RETeval – DR device, which has been developed to evaluate people with diabetes for sight threatening diabetic retinopathy (DR).
A Welch Allyn device and manufactured by LKC, RETeval is the non-mydriatic and non-invasive hand-held ISCEV protocol-compliant visual electrophysiology device.
It can perform both flash Electroretinogram (ERG) and flash visual evoked potential (VEP) testing using skin or corneal electrodes.
Under the deal, Welch Allyn will exclusively distribute RETeval – DR outside the US, which is said to screen people with diabetes for eye disease with a technical failure rate of less than 1%.
LKC will exclusively distribute all RETeval options within the US. It will also exclusively distribute ISCEV compliant protocol version RETeval Complete outside the US through its distribution partners.
LKC Technologies president Jim Datovech said: "We believe that RETeval Complete will bring about an accessibility paradigm shift by enabling functional testing for acquired and inherited retinal eye diseases to be both cost effective and widely accessible to better meet the needs of ophthalmologists, optometrists, and hospitals and the patients that they serve.
"RETeval Complete is completely portable and will be useful to assist in the diagnosis of diseases that are currently detected with much larger ERG/VEP equipment that is not always readily available to those patients in need of such testing, including infant, pediatric and adult patient populations. "
LKC Technologies will exhibit RETeval at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, which will be held from 3 to 6 May.
Image: RETeval device is the non-mydriatic and non-invasive hand-held ISCEV protocol-compliant visual electrophysiology device. Photo: courtesy of PRNewswire/ LKC Technologies, Inc.